R
Rome Therapeutics
Developing novel therapies for cancer and autoimmune diseases treatment by harnessing the power of the repeatome
About Rome Therapeutics
RomeTX is a startup operating in the digital space, providing an innovative and interactive online platform. The company's website, rometx.com, is designed with a user-friendly interface that engages visitors with a dynamic splash screen. The website's functionality includes a toggle feature that allows users to switch the display on and off, providing a unique user experience.
The company primarily serves clients who are looking for a modern and interactive digital experience, which includes businesses across various sectors that want to enhance their online presence. RomeTX operates in the competitive digital market, where the demand for unique and engaging online experiences is high.
RomeTX's business model is centered around providing digital solutions. While the exact monetization strategy is not explicitly stated, it can be inferred that the company generates revenue through providing digital services, which could include website design and development, digital marketing, and other related services.
In conclusion, RomeTX is a dynamic startup offering unique digital experiences. It operates in a competitive market, serving clients across various sectors and generating revenue through the provision of digital services.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jan 2026 | $0 | — | Pretzel | ↗ |
| SERIES BOther financing | Sep 2023 | $72M | $385M | Andreessen Horowitz · GV · Casdin Capital · Mirae Asset Capital | ↗ |
Growth signals
Latest recorded traffic for Rome Therapeutics is 1.7K monthly website visits, down 48.5% over the last three months. Rome Therapeutics's team declined 38.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Rome Therapeutics in the Cambridge ecosystem
The Rome Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A16 investors entered at this stage
GV
ARCH Venture Partners- PFPartners Innovation Fund
Section 32
Andreessen Horowitz
Alexandria Venture Investments
Sanofi Ventures
Casdin Capital
Mass General Brigham Ventures
Mirae Asset Capital
Eurofarma
Luma Group- RORaycap family office
- SOSigmas Group Family Office
Bristol-Myers Squibb
Johnson & Johnson Innovation
Other known investors2 additional known investors
Massachusetts Institute of Technology
Pretzel
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rome Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rome Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







